Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ZFP3-DT (ZFP3 divergent transcript) is annotated as a long noncoding RNA (lncRNA) gene found at the ZFP3 locus. Available data in gene and genomic databases describe ZFP3-DT as a non-protein-coding transcript, but there is no experimentally confirmed biological function, involvement in disease, or validation as a drug target in current biomedical literature[3]. It is distinct from the protein-coding gene ZFP3 (zinc finger protein 3), which is primarily studied in plants and functions as a C2H2-type zinc finger transcription factor involved in the regulation of cell wall biosynthesis and root hair formation in *Arabidopsis thaliana*[1][2]. There is currently no evidence that ZFP3-DT functions as a receptor or any other direct therapeutic target, and its relevance in mammalian or human biology remains unclear[3]. Important contextual note: The main literature describing functional ZFP3 activity pertains to the transcription factor in *Arabidopsis thaliana*[1][2]. ZFP3-DT, as a "divergent transcript," refers to a noncoding RNA transcribed in the opposite direction to the protein-coding ZFP3 gene. No credible sources currently assign ZFP3-DT any canonical biological function, therapeutic relevance, or drug interactions[3]. If you are seeking information about the **plant transcription factor** ZFP3, that is a different entity—a C2H2-type zinc finger transcription factor controlling gene expression involved in plant development and is not a human/animal drug target[1][2]. If you meant the protein-coding ZFP3 or ZFP35 in mammals, clarification is needed, as ZFP3-DT is not equivalent to those targets and is not considered a canonical therapeutic target in standard biomedical usage.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ZFP3 divergent transcript (ZFP3-DT).